Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Darlene M Deptula-hicks is Director at Aldeyra Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Aldeyra TherapeuticsALDX
2 disclosures · Jun 2026
Jun 9, 202685Kdisclosed Jun 11
DetailsOfficial recordJun 9, 20269,756disclosed Jun 11
DetailsOfficial recordDarlene M Deptula-hicks bought shares on the open market in 2016, and has not bought since 2016.
In SEC filings since 2016: the latest open-market purchase is from 2016; no open-market sale is on record.
Palvella Therapeutics (PVLA), from 2016 to 2016: 1 purchase and 0 sales.
Darlene M Deptula-hicks bought shares on the open market in 2016, and has not bought since 2016.
Darlene M Deptula-hicks reported 1 open-market purchase and 0 sales since 2016; purchases in 2016.
| Year | Bought | Sold |
|---|---|---|
| 2016 | $8.3K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Darlene M Deptula-hicks reported 1 open-market purchase and 0 sales here, 2016.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
